StockNews.AI
LTRN
StockNews.AI
145 days

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

1. Lantern Pharma announced Q4 2024 financial results and updates on AI drug candidates. 2. The RADR® platform continues to advance oncology drug discovery and development.

Earnings
-4.83%Current Return
VS
-2%S&P 500
$3.7303/27 04:08 PM EDTEvent Start
$3.5503/28 10:31 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Successful financial results and innovative AI approach can drive investor confidence, similar to past tech-driven biopharma growth stories.

How important is it?

The financial results and portfolio update are crucial for assessing LTRN's growth trajectory and investment attractiveness.

Why Long Term?

If the RADR® platform continues to deliver, it could significantly improve the efficiency and success of drug development, impacting long-term valuation.

Related Companies

BMYMRNAAMGN
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on its portfolio of AI-driven drug candidates, the RADR® platform for precision oncology drug.

Related News